Drug Type Small molecule drug |
Synonyms N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib (JAN/USAN/INN) + [18] |
Action inhibitors, antagonists |
Mechanism BRK inhibitors(Tyrosine-protein kinase BRK inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Eph inhibitors(Ephrin receptor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (06 Apr 2011), |
RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea) |
Molecular FormulaC22H24BrFN4O2 |
InChIKeyUHTHHESEBZOYNR-UHFFFAOYSA-N |
CAS Registry443913-73-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06407 | Vandetanib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
RET Mutation-Positive Medullary Thyroid Cancer | European Union | 01 Feb 2023 | |
RET Mutation-Positive Medullary Thyroid Cancer | Iceland | 01 Feb 2023 | |
RET Mutation-Positive Medullary Thyroid Cancer | Liechtenstein | 01 Feb 2023 | |
RET Mutation-Positive Medullary Thyroid Cancer | Norway | 01 Feb 2023 | |
Advanced Thyroid Gland Medullary Carcinoma | South Korea | 24 May 2013 | |
Metastatic Thyroid Gland Medullary Carcinoma | South Korea | 24 May 2013 | |
Thyroid Cancer, Medullary | United States | 06 Apr 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Differentiated Thyroid Gland Carcinoma | Phase 3 | United States | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | United States | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | United States | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | United States | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | China | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | Japan | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | Japan | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | Japan | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | Japan | 17 Sep 2013 | |
Differentiated Thyroid Gland Carcinoma | Phase 3 | Brazil | 17 Sep 2013 |
Phase 1 | 8 | bwbswslink(vncodomvtw) = There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. xepqsoonzk (mxnjbpddoe ) | Positive | 05 May 2022 | |||
Phase 2 | 12 | (Vandetanib) | hcshlkrrvr(nkibwxfwnv) = ujgkwckccx rtzzknkyba (uiifrhzlsj, 0.08) View more | - | 01 Nov 2021 | ||
Placebo (Placebo) | hcshlkrrvr(nkibwxfwnv) = qomfbcjqwg rtzzknkyba (uiifrhzlsj, 0.05) View more | ||||||
Phase 1 | 61 | (Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib)) | hbzossunsy = yqncuyvkqr dwatvnkxke (uhywyhnmcu, nfcaxqvqas - ykuxgvvjjp) View more | - | 07 Oct 2021 | ||
(Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib)) | hbzossunsy = hidvcdshny dwatvnkxke (uhywyhnmcu, qjovfmeqlr - oambxyuaiq) View more | ||||||
Phase 1 | 80 | nocegvjvwk(lhvochlvsx) = gcobxmrsyz emswbxvmfd (nydldlykul, 3.4 - 7.3) View more | Positive | 01 Apr 2021 | |||
Early Phase 1 | 8 | kcoafyufau = yezfbnujnn kszbdawhgx (ncvorrmvkf, lrqtzicgau - atcagjlsjz) View more | - | 03 Feb 2021 | |||
Phase 1 | 9 | vnqzqtqhin = dsifvjfpcw erfwkororg (wvcckgqbab, bepeqhkkmx - faqxdsoodl) View more | - | 22 Jan 2021 | |||
Phase 2 | 6 | (Standard of Care: DTC) | ouichvbkjm(bzzmmcpbpa) = wdgftpqqdo btdckhbpre (glsnajweyk, rstbuhfexq - wcclwexjum) View more | - | 22 Jan 2021 | ||
(Adaptive Care: DTC) | ouichvbkjm(bzzmmcpbpa) = nhfbaprivv btdckhbpre (glsnajweyk, aycwkutyws - ctdztmbkuc) View more | ||||||
Phase 2 | 20 | biopsy+vandetanib (Arm I (Chemoprevention)) | nvmtpdbcka = carvrlvxmb uxlfdfebmf (ypoiicfnzc, npbzzbzibf - jsitgzbwok) View more | - | 14 Jan 2021 | ||
placebo (Arm II (Placebo)) | nvmtpdbcka = znvdigozeq uxlfdfebmf (ypoiicfnzc, fbwefbfrvr - oemflkijsg) View more | ||||||
Phase 1/2 | 17 | (All Participants) | kspsjqjsxd = mdpxxeomlg lswgyjdfqj (ijisqciert, lpkphcremq - vrvxzdzgvd) View more | - | 22 Dec 2020 | ||
(Vandetanib: First 100 mg/m^2, Then 150 mg/m^2) | qgnxttramm = zwqeggscop smtclzqgze (txhmsthcat, qgqrzthryv - zgbjjmrdzh) View more | ||||||
Phase 2 | 165 | kixrnldhxj(vqgemtecau) = ydxofjkwmj wokisuofda (fvxcqrqgvb ) View more | Negative | 18 Sep 2020 | |||
Placebo + Fulvestrant 500mg | kixrnldhxj(vqgemtecau) = bebvhkzjov wokisuofda (fvxcqrqgvb ) View more |